Which has the lower trailing P/E, CORT or PEN?

PEN has the lower trailing P/E: CORT trades at 290.55 and PEN at 77.91. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CORT or PEN?

Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus PEN at 17.52%.

Is CORT or PEN more profitable?

PEN runs the higher net margin — CORT at 6.61% versus PEN at 10.67%.

How have CORT and PEN total returns compared?

Over the past 10 years, CORT delivered 33.70% and PEN delivered 15.63% annualized total return. Past performance doesn't predict future results.

Corcept Therapeutics Incorporated (CORT) vs Penumbra, Inc. (PEN)

A side-by-side comparison of Corcept Therapeutics Incorporated and Penumbra, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CORT

Corcept Therapeutics Incorporated

$13.19B

$122.03HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

PEN

Penumbra, Inc.

$12.49B

$317.11HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — CORT vs PEN

growth of $100 · dividends reinvested · last 10y

CORT +1837.0% (+34.5%/yr)PEN +327.2% (+15.6%/yr)CORT compounded faster over this window

CORT PEN

CORT vs PEN: by the numbers

•CORT is the larger company ($13.19B vs $12.49B market cap).
•PEN trades at the lower trailing earnings multiple (77.91 vs 290.55 P/E), one valuation lens rather than an overall verdict.
•PEN converts more revenue to profit (10.67% vs 6.61% net margin).
•CORT grew revenue faster over the past five years (19.35% vs 17.52% CAGR).

Metrics side by side

Valuation

Metric	CORT	PEN
P/E ratio	290.55	77.91
Forward P/E	N/A	67.36
P/S ratio	15.88	8.30
P/B ratio	18.69	8.16
EV / EBITDA	1483.24	61.12
FCF yield	0.81%	1.73%

Profitability

Metric	CORT	PEN
Gross margin	98.30%	67.84%
Operating margin	0.77%	12.45%
Net margin	6.61%	10.67%
ROE	7.78%	10.49%
ROIC	0.87%	8.48%

Growth (annualized)

Metric	CORT	PEN
Revenue CAGR (5Y)	19.35%	17.52%
EPS CAGR (5Y)	0.64%	N/A
FCF CAGR (5Y)	-4.40%	N/A
Total return CAGR (5Y)	43.90%	4.16%

Frequently asked

Which has the lower trailing P/E, CORT or PEN?: PEN has the lower trailing P/E: CORT trades at 290.55 and PEN at 77.91. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CORT or PEN?: Over the past five years, CORT grew revenue faster — CORT at a 19.35% CAGR versus PEN at 17.52%.
Is CORT or PEN more profitable?: PEN runs the higher net margin — CORT at 6.61% versus PEN at 10.67%.
How have CORT and PEN total returns compared?: Over the past 10 years, CORT delivered 33.70% and PEN delivered 15.63% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CORT analysis Full PEN analysis Interactive comparison tool

Dig into the metrics

Corcept Therapeutics P/E ratio Penumbra P/E ratio Corcept Therapeutics ROE Penumbra ROE Corcept Therapeutics operating margin Penumbra operating margin Corcept Therapeutics revenue growth Penumbra revenue growth Corcept Therapeutics free cash flow Penumbra free cash flow

Corcept Therapeutics & Penumbra appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.